B-UVB phototherapy versus Excimerlaser after minigrafting in vitiligo patients

• Conditions: vitiligo; 10035023

• Registration Number: NL-OMON29736
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

i. Consecutive patients, diagnosed with stable vitiligo vulgaris* with symmetrical vitiligo patches
*Vitiligo vulgaris: a few to many widespread depigmented macules over the entire body, with often a symmetrically distribution pattern.
Stable means: no expansion of existing lesions or appearance of new lesions during the previous 6 months, absence of Koebner*s phenomenon and a positive minigrafting test
ii. Patients, eligible for minigrafting and NB-UVB/excimer therapy
iii. Adult patients: * 18 years
iv. Patients who have given written informed consent

Exclusion Criteria

Patients:
i. With a history of hypertrophic scarring and/or keloid
ii History of allergic/phototoxic reaction (Lidocaine, Tegaderm, Suture strips, sunlight)
iii With a negative minigrafting test
iv With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member)
v. With a personal history of photosensitivity and/or phototoxicity disorders
vi. With skin type I (according to Fitzpatrick classification I-VI)
vii. Who are pregnant
viii. Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s)
ix. With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema.
x. Who are not able to have 2 times weekly NB-UVB/Excimer therapy.
xi. With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weekswill be required.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Percentage, start and grade of repigmentation</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Patient satisfaction</p><br>